Replies to post #189208 on Biotech Values

[ghmm]

AAVL:

Ohad took a position in his model portfolio but acknowledged it as high-risk, high-reward.
http://www.orf-blog.com/will-2015-mark-the-turnaround-for-antibody-drug-conjugates/#comments

I wonder how a basket of these high-risk, high-reward stocks will do. No position in AAVL though I do own one high-risk, high-reward that has been discussed on this board of late :-).